News | January 20, 2023
Blue Jet Healthcare gets SEBI nod for IPO
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
This will give either party customers access enzyme expertise and assets, resulting in cost-effective, green processing for API manufacturing.
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
.jpg)
Evonik's six innovation growth fields are: Sustainable nutrition, healthcare solutions, advanced food ingredients, membranes, cosmetic solutions, and additive manufacturing
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
The expansion positions Cambrex with the largest and most advanced API facility in the United States
The plant is scheduled to come on stream in September 2024
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
Subscribe To Our Newsletter & Stay Updated
